The pipeline spans pancreatic cancer development (CypCaps), diabetes engineering (insulin-producing stem cells), and cannabinoid therapies for brain cancer. However, as of December 1, 2025, the company received notice from NASDAQ that it failed to maintain the minimum $1.00 bid price requirement for continued listing, and CEO Kenneth Waggoner stepped down with the board authorizing a business review committee to evaluate strategic opportunities.
Cyborg Score Rationale
PharmaCyte remains a micro-cap entity facing significant headwinds. The company faces regulatory challenges, leadership transitions, and stock price deterioration below NASDAQ listing requirements, creating uncertainty about near-term value realization despite proprietary technology.
Top Insights
Cell-in-a-Box technology encapsulates live cells for therapies targeting cancer, diabetes, and malignant ascites
NASDAQ delisting risk as of December 2025 due to sustained sub-$1.00 bid price
Leadership transition with CEO departure and board-authorized strategic review process underway
Asset diversification through TNF Pharmaceuticals interest management announced in late 2023-early 2024
Named Competitors
CAR-T Therapies — Cell therapy for hematologic malignancies
Gene Therapy Platform — Gene and cell therapies for severe diseases